Induction of PD-L1 expression by the EML4–ALK oncoprotein and downstream signaling pathways in non–small cell lung cancer

K Ota, K Azuma, A Kawahara, S Hattori, E Iwama… - Clinical cancer …, 2015 - AACR
Purpose: Therapies targeted to the immune checkpoint mediated by PD-1 and PD-L1 show
antitumor activity in a subset of patients with non–small cell lung cancer (NSCLC). We have …

[HTML][HTML] Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer

H Ishii, K Azuma, A Kawahara, K Yamada… - Journal of thoracic …, 2015 - Elsevier
Background Programmed cell death 1 receptor–ligand interaction is a major pathway often
hijacked by tumors to suppress immune control. The aim of this retrospective study was to …

[HTML][HTML] Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent …

T Tokito, K Azuma, A Kawahara, H Ishii… - European journal of …, 2016 - Elsevier
Background Expression of programmed cell death-ligand 1 (PD-L1) is known to be a
mechanism whereby cancer can escape immune surveillance, but little is known about …

Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor–activating …

C Yamamoto, Y Basaki, A Kawahara, K Nakashima… - Cancer research, 2010 - AACR
Abstract Gefitinib (Iressa) and erlotinib (Tarceva), which target the epidermal growth factor
receptor (EGFR), are approved for treatment of patients with advanced non–small cell lung …

Tumor Growth Suppression in Pancreatic Cancer by a Putative Metastasis Suppressor Gene Cap43/NDRG1/Drg-1 through Modulation of Angiogenesis

Y Maruyama, M Ono, A Kawahara, T Yokoyama… - Cancer research, 2006 - AACR
Cap43 has been identified as a nickel-and calcium-induced gene, and is also known as N-
myc downstream-regulated gene 1 (NDRG1), Drg-1 and rit42. It is also reported that …

Erlotinib resistance in lung cancer cells mediated by integrin β1/Src/Akt-driven bypass signaling

R Kanda, A Kawahara, K Watari, Y Murakami… - Cancer research, 2013 - AACR
EGF receptor (EGFR) kinase inhibitors, including gefitinib and erlotinib, exert potent
therapeutic efficacy in non–small cell lung cancers harboring EGFR-activating mutations …

[HTML][HTML] FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis

M Takenaka, N Seki, U Toh… - Molecular and …, 2013 - spandidos-publications.com
The forkhead box protein 3 (FOXP3) transcription factor is highly expressed in tumor cells as
well as in regulatory T cells (Tregs). It plays a tumor-enhancing role in Tregs and suppresses …

Molecular diagnosis of activating EGFR mutations in non–small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis

A Kawahara, C Yamamoto, K Nakashima… - Clinical Cancer …, 2010 - AACR
Purpose: Therapeutic responses of non–small cell lung carcinoma (NSCLC) to epidermal
growth factor receptor (EGFR)–targeted drugs, such as gefitinib and erlotinib, are closely …

[HTML][HTML] FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitor

K Azuma, A Kawahara, K Sonoda, K Nakashima… - Oncotarget, 2014 - ncbi.nlm.nih.gov
Most NSCLC patients with EGFR mutations benefit from treatment with EGFR-TKIs, but the
clinical efficacy of EGFR-TKIs is limited by the appearance of drug resistance. Multiple …

N-myc downstream regulated gene 1/Cap43 suppresses tumor growth and angiogenesis of pancreatic cancer through attenuation of inhibitor of κB kinase β …

F Hosoi, H Izumi, A Kawahara, Y Murakami… - Cancer research, 2009 - AACR
N-myc downstream regulated gene 1 (NDRG1)/Cap43 expression is a predictive marker of
good prognosis in patients with pancreatic cancer as we reported previously. In this study …